Previous 10 | Next 10 |
SOUTH SAN FRANCISCO, Calif., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that Sabah Oney, Ph.D., chief business officer, will participate in a fireside chat at the BTIG Virtual Biote...
Shares in Alector (NASDAQ: ALEC) are tumbling 28.7% at 12:30 p.m. EDT on Wednesday over concerns COVID-19 could negatively impact patient enrollment and monitoring in clinical-stage trials of AL001. The biotech company 's AL001 is being evaluated for use in frontotemporal dementia patients...
Gainers: Eastman Kodak (NYSE: KODK ) +319% . More news on: Eastman Kodak Company, Tupperware Brands Corporation, Sonoma Pharmaceuticals, Inc., Stocks on the move, , Read more ...
Alector (NASDAQ: ALEC ) is down 25% premarket on average volume on the heels of preliminary data from its Phase 1b and open-label Phase 2 trials evaluating lead candidate AL001 in patients with frontotemporal dementia (FTD) with a progranulin gene (GRN) mutation, a subset o...
Boxlight (NASDAQ: BOXL ) -27% after pricing equity offering. More news on: Boxlight Corporation, Global Eagle Entertainment Inc., Sypris Solutions, Inc., Stocks on the move, , Read more ...
The following slide deck was published by Alector, Inc. in conjunction with this Read more ...
AL001 was generally safe and well-tolerated in Phase 1b study and after continuous dosing in 15 asymptomatic and symptomatic FTD-GRN participants in Phase 2 study Treatment with AL001 in Phase 2 study resulted in sustained restoration of plasma progranulin levels in all FTD-GRN parti...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...
Premarket - Albertsons (NYSE: ACI ) will issue its first earnings report since the IPO. The stock attracted a wave of bullish ratings last month and is likely to have seen a positive effect on sales from the pandemic. The last grocery store operator to go public before Albertsons w...
Trial will enroll up to 180 symptomatic and pre-symptomatic participants with FTD- GRN gene mutation at multiple sites in the U.S., Europe and Australia There are currently no FDA-approved treatments for frontotemporal dementia SOUTH SAN FRANCISCO, Calif., July 24, 2020 (GLOBE N...
News, Short Squeeze, Breakout and More Instantly...
--INVOKE-2 is the first global Phas e 2 trial evaluating the safety and efficacy of a TREM2 agonist, AL002, in slowing disease progression in individuals with early Alzheimer’s disease (AD)-- --Baseline characteristics data for the INVOKE-2 study confirm a representative stud...
SOUTH SAN FRANCISCO, Calif., July 23, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced presentations related to the Company’s TREM2 and progranulin programs at the upcoming Alzheimer's Associatio...
SOUTH SAN FRANCISCO, Calif., June 20, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that management will participate in a corporate presentation at the H.C. Wainwright 5 th Annual Neuro Pers...